Generic Name:
mavacamten
Project Status:
Active
Therapeutic Area:
Obstructive hypertrophic cardiomyopathy
Manufacturer:
Bristol Myers Squibb
Brand Name:
Camzyos
Project Line:
Reimbursement Review
Project Number:
SR0755-000
NOC Status at Filing:
Pre NOC
Details
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients, aligned with the pivotal phase 3 EXPLORER-HCM patient population.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) Class II-III in adult patients.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.